Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 201–300 of 1,018
Calmodulin-Dependent Protein Kinase II: Linking Heart Failure and Arrhythmias
Swaminathan, P. D., Purohit, A., Hund, T. J., & Anderson, M. E. (2012) · Circulation Research · doi:10.1161/circresaha.111.243956 · Cited by 283
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 288
Gender and the renin–angiotensin–aldosterone system
Komukai, K., Mochizuki, S., & Yoshimura, M. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00854.x · Cited by 291
Holubarsch, C. J. F., Rohrbach, M., Karrasch, M., Boehm, E., Polonski, L., Ponikowski, P., & Rhein, S. (2007) · Clinical Science · doi:10.1042/cs20060307 · Cited by 287
Forrest, M. J., Bloomfield, D., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 292
Grune, J., Beyhoff, N., Smeir, E., Chudek, R., Blumrich, A., Ban, Z., Brix, S., Betz, I. R., Schupp, M., Foryst-Ludwig, A., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10360 · Cited by 292
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J., & Townend, J. N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.066 · Cited by 286
Caprio, M., Newfell, B. G., la Sala, A., Baur, W., Fabbri, A., Rosano, G., Mendelsohn, M. E., & Jaffe, I. Z. (2008) · Circulation Research · doi:10.1161/circresaha.108.174235 · Cited by 285
Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias
Ouvrard-Pascaud, A., Sainte-Marie, Y., Bénitah, J.-P., Perrier, R., Soukaseum, C., Cat, A. N. D., Royer, A., Le Quang, K., Charpentier, F., Demolombe, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.503706 · Cited by 272
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
Weir, R. A. P., Miller, A. M., Murphy, G. E. J., Clements, S., Steedman, T., Connell, J. M. C., McInnes, I. B., Dargie, H. J., & McMurray, J. J. V. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.047 · Cited by 280
Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure
van der Harst, P., van der Steege, G., de Boer, R. A., Voors, A. A., Hall, A. S., Mulder, M. J., van Gilst, W. H., & van Veldhuisen, D. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.027 · Cited by 281
Pitzalis, M. V., Iacoviello, M., Romito, R., Guida, P., De Tommasi, E., Luzzi, G., Anaclerio, M., Forleo, C., & Rizzon, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.058 · Cited by 284
Villamil, A., Chrysant, S. G., Calhoun, D., Schober, B., Hsu, H., Matrisciano-Dimichino, L., & Zhang, J. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280103a6b · Cited by 285
Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline
Heart Failure Society of America (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.04.005 · Cited by 276
Observational Study Mortality in Treated Primary Aldosteronism: The German Conn's Registry
Reincke, M., Fischer, E., Gerum, S., Merkle, K., Schulz, S., Pallauf, A., Quinkler, M., Hanslik, G., Lang, K., Hahner, S., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197111 · Cited by 278
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 283
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Central regulation of sodium appetite
Geerling, J. C., & Loewy, A. D. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.039891 · Cited by 274
Resistant Hypertension, Obesity, Sleep Apnea, and Aldosterone: Theory and Therapy
Goodfriend, T. L., & Calhoun, D. A. (2004) · Hypertension · doi:10.1161/01.hyp.0000116223.97436.e5 · Cited by 279
A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone
Struthers, A., Krum, H., & Williams, G. H. (2008) · Clinical Cardiology · doi:10.1002/clc.20324 · Cited by 267
Desai, A. S., Lewis, E. F., Li, R., Solomon, S. D., Assmann, S. F., Boineau, R., Clausell, N., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.007 · Cited by 274
Self-citationBärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 270
Vardeny, O., Wu, D. H., Desai, A., Rossignol, P., Zannad, F., Pitt, B., & Solomon, S. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.048 · Cited by 272
Self-citationIraqi, W., Rossignol, P., Angioi, M., Fay, R., Nuée, J., Ketelslegers, J. M., Vincent, J., Pitt, B., & Zannad, F. (2009) · Circulation · doi:10.1161/circulationaha.108.809194 · Cited by 260
Self-citation2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Antiarrhythmic effect of carvedilol after acute myocardial infarction
McMurray, J., Køber, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. N., & Ford, I. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.076 · Cited by 275
Self-citationFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi397 · Cited by 272
Izawa, H., Murohara, T., Nagata, K., Isobe, S., Asano, H., Amano, T., Ichihara, S., Kato, T., Ohshima, S., Murase, Y., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.571653 · Cited by 268
Stowasser, M., Sharman, J., Leano, R., Gordon, R. D., Ward, G., Cowley, D., & Marwick, T. H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0681 · Cited by 271
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology, (. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4103 · Cited by 244
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 258
Echocardiography in Heart Failure
Kirkpatrick, J. N., Vannan, M. A., Narula, J., & Lang, R. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.048 · Cited by 219
Kolkhof, P., & Bärfacker, L. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0600 · Cited by 262
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
Aldosterone, Inflammation, Immune System, and Hypertension
Ferreira, N. S., Tostes, R. C., Paradis, P., & Schiffrin, E. L. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpaa137 · Cited by 248
Solomon, S. D., Wang, D., Finn, P., Skali, H., Zornoff, L., McMurray, J. J. V., Swedberg, K., Yusuf, S., Granger, C. B., Michelson, E. L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000144474.65922.aa · Cited by 266
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000207 · Cited by 259
Mihailidou, A. S., Loan Le, T. Y., Mardini, M., & Funder, J. W. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136242 · Cited by 262
Barrera-Chimal, J., Lima-Posada, I., Bakris, G. L., & Jaisser, F. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00490-8 · Cited by 252
Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2116 · Cited by 261
Daskalopoulou, S. S., Khan, N. A., Quinn, R. R., Ruzicka, M., McKay, D. W., Hackam, D. G., Rabkin, S. W., Rabi, D. M., Gilbert, R. E., Padwal, R. S., et al. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.02.018 · Cited by 266
Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure
Qin, W., Rudolph, A. E., Bond, B. R., Rocha, R., Blomme, E. A. G., Goellner, J. J., Funder, J. W., & McMahon, E. G. (2003) · Circulation Research · doi:10.1161/01.res.0000080521.15238.e5 · Cited by 262
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Costello-Boerrigter, L. C., Smith, W. B., Boerrigter, G., Ouyang, J., Zimmer, C. A., Orlandi, C., & Burnett, J. C. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00195.2005 · Cited by 264
Bauersachs, J., Jaisser, F., & Toto, R. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04488 · Cited by 257
Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
Akpek, M., Ozdogru, I., Sahin, O., Inanc, M., Dogan, A., Yazici, C., Berk, V., Karaca, H., Kalay, N., Oguzhan, A., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.196 · Cited by 258
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
Struthers, A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.11.037 · Cited by 257
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Aldosterone and Vascular Inflammation
Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.095489 · Cited by 256
Franconi, F., & Campesi, I. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12362 · Cited by 251
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Eschalier, R., McMurray, J. J. V., Swedberg, K., van Veldhuisen, D. J., Krum, H., Pocock, S. J., Shi, H., Vincent, J., Rossignol, P., Zannad, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.086 · Cited by 247
Self-citationHow Dangerous Is Hyperkalemia?
Montford, J. R., & Linas, S. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121344 · Cited by 236
Aldosterone antagonists for preventing the progression of chronic kidney disease
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub3 · Cited by 189
Keidar, S., Kaplan, M., Pavlotzky, E., Coleman, R., Hayek, T., Hamoud, S., & Aviram, M. (2004) · Circulation · doi:10.1161/01.cir.0000127949.05756.9d · Cited by 244
Dan, G.-A., Martinez-Rubio, A., Agewall, S., Boriani, G., Borggrefe, M., Gaita, F., van Gelder, I., Gorenek, B., Kaski, J. C., Kjeldsen, K., et al. (2018) · EP Europace · doi:10.1093/europace/eux373 · Cited by 229
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone
He, B. J., Joiner, M.-L. A., Singh, M. V., Luczak, E. D., Swaminathan, P. D., Koval, O. M., Kutschke, W., Allamargot, C., Yang, J., Guan, X., et al. (2011) · Nature Medicine · doi:10.1038/nm.2506 · Cited by 240
Møller, J. E., Hillis, G. S., Oh, J. K., Reeder, G. S., Gersh, B. J., & Pellikka, P. A. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.042 · Cited by 241
Heart failure as an autonomic nervous system dysfunction
Kishi, T. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2011.12.006 · Cited by 227
Mineralocorticoid Receptors: Distribution and Activation
Funder, J. W. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2344-2 · Cited by 229
Chronic Heart Failure: Contemporary Diagnosis and Management
Ramani, G. V., Uber, P. A., & Mehra, M. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0494 · Cited by 236
Reverse remodeling in heart failure—mechanisms and therapeutic opportunities
Koitabashi, N., & Kass, D. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.172 · Cited by 236
Hirata, A., Maeda, N., Hiuge, A., Hibuse, T., Fujita, K., Okada, T., Kihara, S., Funahashi, T., & Shimomura, I. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp191 · Cited by 236
Beldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Van Spall, H. G. C., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 216
Triage After Hospitalization With Advanced Heart Failure
O'Connor, C. M., Hasselblad, V., Mehta, R. H., Tasissa, G., Califf, R. M., Fiuzat, M., Rogers, J. G., Leier, C. V., & Stevenson, L. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.083 · Cited by 233
Aldosterone as a Mediator of Cardiovascular Damage
Buffolo, F., Tetti, M., Mulatero, P., & Monticone, S. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.17964 · Cited by 228
Fraccarollo, D., Berger, S., Galuppo, P., Kneitz, S., Hein, L., Schütz, G., Frantz, S., Ertl, G., & Bauersachs, J. (2011) · Circulation · doi:10.1161/circulationaha.110.983023 · Cited by 226
Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L., & Mukherjee, R. (2008) · Circulation · doi:10.1161/circulationaha.108.778811 · Cited by 235
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Aldosterone and end-organ damage
Marney, A. M., & Brown, N. J. (2007) · Clinical Science · doi:10.1042/cs20070123 · Cited by 212
Tsybouleva, N., Zhang, L., Chen, S., Patel, R., Lutucuta, S., Nemoto, S., DeFreitas, G., Entman, M., Carabello, B. A., Roberts, R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000121426.43044.2b · Cited by 232
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
Fonarow, G. C., Yancy, C. W., Hernandez, A. F., Peterson, E. D., Spertus, J. A., & Heidenreich, P. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.027 · Cited by 230
Manrique, C., Lastra, G., Gardner, M., & Sowers, J. R. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.014 · Cited by 224
Drug dosing adjustments in patients with chronic kidney disease.
Munar, M. Y., & Singh, H. (2007) · PubMed · Cited by 307
Time Dependence of Mortality Risk and Defibrillator Benefit After Myocardial Infarction
Wilber, D. J., Zareba, W., Hall, W. J., Brown, M. W., Lin, A. C., Andrews, M. L., Burke, M., & Moss, A. J. (2004) · Circulation · doi:10.1161/01.cir.0000121328.12536.07 · Cited by 232
Prognostic Value of Health Status in Patients With Heart Failure After Acute Myocardial Infarction
Soto, G. E., Jones, P., Weintraub, W. S., Krumholz, H. M., & Spertus, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000136991.85540.a9 · Cited by 230
Matsumoto, Y., Mori, Y., Kageyama, S., Arihara, K., Sugiyama, T., Ohmura, H., Yakushigawa, T., Sugiyama, H., Shimada, Y., Nojima, Y., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.056 · Cited by 223
Nagata, K., Obata, K., Xu, J., Ichihara, S., Noda, A., Kimata, H., Kato, T., Izawa, H., Murohara, T., & Yokota, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000203772.78696.67 · Cited by 223
Calhoun, D. A., White, W. B., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M. P., & Ménard, J. (2011) · Circulation · doi:10.1161/circulationaha.111.029892 · Cited by 227
Plasma aldosterone is independently associated with the metabolic syndrome
Bochud, M., Nussberger, J., Bovet, P., Maillard, M. R., Elston, R. C., Paccaud, F., Shamlaye, C., & Burnier, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000231338.41548.fc · Cited by 226
Rosenthal, D., Chrisant, M. R. K., Edens, E., Mahony, L., Canter, C., Colan, S., Dubin, A., Lamour, J., Ross, R., Shaddy, R., et al. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.03.018 · Cited by 228
Heart Failure After Myocardial Infarction: Clinical Implications and Treatment
Minicucci, M. F., Azevedo, P. S., Polegato, B. F., Paiva, S. A. R., & Zornoff, L. A. M. (2011) · Clinical Cardiology · doi:10.1002/clc.20922 · Cited by 220
Adverse Remodeling and Reverse Remodeling After Myocardial Infarction
Bhatt, A. S., Ambrosy, A. P., & Velazquez, E. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0876-4 · Cited by 210
Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension
Grobe, J. L., Mecca, A. P., Mao, H., & Katovich, M. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01170.2005 · Cited by 222
Primary aldosteronism: diagnostic and treatment strategies
Mattsson, C., & Young, W. F. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0151 · Cited by 219
Deswal, A., Richardson, P., Bozkurt, B., & Mann, D. L. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.04.007 · Cited by 210
Aldosterone Potentiates Angiotensin II–Induced Signaling in Vascular Smooth Muscle Cells
Mazak, I., Fiebeler, A., Muller, D. N., Park, J.-K., Shagdarsuren, E., Lindschau, C., Dechend, R., Viedt, C., Pilz, B., Haller, H., et al. (2004) · Circulation · doi:10.1161/01.cir.0000131860.80444.ab · Cited by 218
Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M. N., Masoudi, F. A., & Nallamothu, B. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.012 · Cited by 216
Assmus, B., Fischer-Rasokat, U., Honold, J., Seeger, F. H., Fichtlscherer, S., Tonn, T., Seifried, E., Schächinger, V., Dimmeler, S., & Zeiher, A. M. (2007) · Circulation Research · doi:10.1161/01.res.0000264508.47717.6b · Cited by 217
Nanthakumar, K., Epstein, A. E., Kay, G. N., Plumb, V. J., & Lee, D. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.054 · Cited by 217
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Guidelines, S. (2006) · Hypertension Research · Cited by 216
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Japanese Society of Hypertension (2006) · Hypertension Research · doi:10.1291/hypres.29.s1 · Cited by 216
The Renin-Angiotensin-Aldosterone System and Heart Failure
Sayer, G., & Bhat, G. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.002 · Cited by 205
Germano, J. J., Reynolds, M., Essebag, V., & Josephson, M. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.048 · Cited by 221
The selection and use of essential medicines.
Kazembe, P. N., Fannah, J. A., Hoppu, K., Zisovska, E., Pedersen, H., Hill, S., Ondari, C. O., Terlouw, D. J., Mattison, D. R., Zhi-ping, L., et al. (2004) · PubMed · Cited by 215
Zhou, M.-S., Schulman, I. H., & Zeng, Q. (2012) · Vascular Medicine · doi:10.1177/1358863x12450094 · Cited by 207
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.